XERS · Xeris Biopharma Holdings, Inc.
Market Cap
$1.52B
Shares
182.32M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$8.44
Open$8.45
Day$8.29–8.49
52W close$5.29–9.90
Avg vol 30d1.6M
Short int8.7M · 4.8% float · 4.4d
Short vol56%
Last earningsAug 6, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 5, 2026
Est · unconfirmed
· in 9 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.70
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+20%
above
Price vs 50-day avg
+2%
above
RSI (14)
51
neutral
MACD trend
Negative
52-week position
68%
mid-range
Momentum
relative strength
1-month return
+4%
trailing
6-month return
+45%
trailing
YTD return
+8%
this year
Relative strength
+32%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $8 › 200d $7 — 50d above 200d
Institutional flow
Accumulating
+1% holders QoQ · +35 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
4.79% of float · ▼ -5.3% MoM · 4.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
239 holders — near 3-yr high, broad support
Squeeze score
64
elevated · 0–100
Fundamentals
Revenue growth
+143%
Y/Y
EPS growth
+100%
Y/Y
Free cash flow
$27.5M
Balance sheet
$109.3M
net debt
Quant / Vol
risk profile
Volatility
52%
annualized · 1-yr
Max drawdown
−47%
past year
ATR
3.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+20%
Bullish
Price vs 50-day avg
+2%
Bullish
RSI (14)
51
Neutral
MACD trend
Negative
Bearish
52-week position
68%
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $8 › 200d $7 — 50d above 200d
Institutional flow
Accumulating
+1% holders QoQ · +35 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
4.79% of float · ▼ -5.3% MoM · 4.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
239 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $5
Now $8 · 68%
Range high $10
vs 200-day avg +20%
vs 50-day avg +2%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
XERS
this stock
Xeris Biopharma Holdings, Inc.
|
$1.52B | +7.5% | +142.7% | — | 4.8% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$66.37B | — | — | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$57.58B | +15.3% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$49.38B | -0.1% | — | — | 0.0% |
|
HLN
Haleon plc
|
$44.46B | -0.8% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| XERS | -3.4% | +3.8% | +45.0% | +4.5% | +7.5% |
| SPY | +0.5% | +1.2% | +13.3% | +2.7% | +12.5% |
| vs SPY | -3.9% | +2.6% | +31.8% | +1.8% | -5.0% |
Key facts
CIK
1867096
CUSIP
98422E103
13F (30d)
198 filings
197 filers
Visit website
Investor relations